Efficacy and Safety Study of NeuVax™ (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence

Completed · Phase 3

Conditions studied: Breast Cancer With Low to Intermediate HER2 Expression

In brief

Purpose of this trial: 1. To assess the efficacy and safety of NeuVax™ administered with adjuvant Leukine® (sargramostim, GM-CSF). 2. To evaluate and compare the disease free survival (DFS) in the vaccinated and control subjects.

Key facts

Study ID
NCT01479244
Run by
Galena Biopharma, Inc.
People needed
758
Starts
2011-11-01
Expected to finish
2016-09-21
Last updated by the study team
2017-02-27

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.